Insulin glargine in the treatment of type 1 and type 2 diabetes

Vascular Health and Risk Management

Volumn 2, Issue 1, 2006, Pages 59-67

  Barnett, Anthony H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Basal insulin therapy; Diabetes; Insulin glargine; Review

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG SELF ADMINISTRATION; FETOTOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; LONG TERM CARE; MICROANGIOPATHY; MITOGENESIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SATISFACTION; PREGNANCY DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 33646058259     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.1.59     Document Type: Review

References (52)

1. Bahr M, Kolter T, Seipke G, et al. 1997. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol, 320:259-65.
2. Berti L, Kellerer M, Bossenmaier B, et al. 1998. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res, 30: 123-9.
3. Bohannon NJV. 2003. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgraduate Medicine. Postgrad Med, 113:39-42, 45-8, 54.
4. Bolli GB, Owens DR. 2000. Insulin glargine. Lancet, 356:443-5.
5. Campbell RK, White JR Jr. 2002. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash), 42:602-11.
6. Ciaraldi TP, Carter L, Seipke G, et al. 2001. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab, 86: 5838-47.
7. Cryer PE. 1999. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev, 15:42-6.
8. Davies M, Storms F, Shutler S, et al. 2005. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care, 28:128-8.
9. [DCCT] DCCT Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329:977-86.
10. [DCCT/EDIC] DCCT/EDIC Research Group. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med, 342:381-9.
11. Devlin JT, Hothersall L, Wilkis JL. 2002. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care, 25:1095-6.
12. Di Cianni G, Volpe L, Lencioni C, et al. 2005. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care, 28:982-3.
13. Dixon AN, Bain SC. 2005. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus. BMJ, 330:455.
14. Dunn CJ, Plosker GL, Keating GM, et al. 2003. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 63:1743-78.
15. Feher M, Bailey C. 2004. Reclassifying insulins. Br J Diabetes Vasc Dis, 1:39-42.
16. Gallen IW, Carter C. 2003. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients. Diabetes Care, 26:3352-3.
17. Garg SK, Paul JM, Karsten JI, et al. 2004. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther, 6:589-95.
18. Gillies PS, Figgitt DP, Lamb HM. 2000. Insulin glargine. Drugs, 59: 253-60.
19. Heinemann L, Linkeschova R, Rave K, et al. 2000. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care, 23:644-9.
20. Heinemann L, Richter B. 1993. Clinical pharmacology of human insulin. Diabetes Care, 16(Suppl 3):90-100.
21. Hershon KS, Blevins TC. 2004. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract, 10:10-17.
22. Hirsch IB. 1998. Intensive treatment of type 1 diabetes. Med Clin North Am, 82:689-719.
23. Holstein A, Plaschke A, Egberts EH. 2003. Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Diabet Med, 20:779-80.
24. Home PD, Boulton AJM, Jimenez J, et al; on behalf of the Worldwide Initiative for Diabetes Education (WorldWIDE). 2003. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diab Int, 20:63-71.
25. Jehle PM, Micheler C, Jehle DR, et al. 1999. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet, 354:1604-7.
26. Kudva YC, Basu A, Jenkins GD, et al. 2005. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care, 28:10-14.
27. Kurtzhals P, Schaffer L, Sorensen A, et al. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 49:999-1005.
28. LANTUS® 2004. Insulin glargine (rDNA origin) injection. Prescribing Information. Aventis Pharmaceuticals, Inc. Kansas City, MO 64137, USA. Revised August 2004.
29. Lepore M, Pampanelli S, Fanelli C, et al. 2000. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 49:2142-8.
30. Nathan DM, Lachin J, Cleary P, et al. 2003. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med, 348:2294-303.
31. Nathan DM, Cleary PA, Backlund JY, et al. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 353:2643-53.
32. NICE. 2002. Appraisal consultation document: The clinical effectiveness and cost effectiveness of long-acting insulin analogues for diabetes [online]. Accessed October 2005. URL: http://www.nice.org.uk/article.asp?a=35497.
33. Owens DR, Coates PA, Luzio SD, et al. 2000. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care, 23:813-19.
34. Pieber TR, Eugene-Jolchine I, Derobert E. 2000. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care, 23:157-62.
35. Putz D, Kabadi UM. 2002. Insulin glargine in continuous enteric tube feeding. Diabetes Care, 25:1889-90.
36. Raskin P, Klaff L, Bergenstal R, et al. 2000. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care, 23:1666-71.
37. Ratner RE, Hirsch IB, Neifing JL, et al. 2000. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care, 23:639-43.
38. Riddle MC, Rosenstock J, Gerich J. 2003. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 26:3080-6.
39. Rosenstock J, Dailey G, Massi-Benedetti M, et al. 2005. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 28:950-5.
40. Rosenstock J, Park G, Zimmerman J. 2000. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care, 23:1137-42.
41. Rosenstock J, Schwartz SL, Clark CM Jr, et al. 2001. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care, 24:631-6.
42. Rosskamp RH, Park G. 1992. Long-acting insulin analogs. Diabetes Care, 22(Suppl 2):B109-13.
43. Schober E, Schoenle E, Van Dyk J, et al. 2001. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care, 24:2005-6.
44. [UKPDS] UKPDS Study Group. 1995a. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ, 310:83-8.
45. [UKPDS] UKPDS Study Group. 1995b. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study (UKPDS) Group. Diabetes, 44:1249-58.
46. [UKPDS] UKPDS Study Group. 1998a. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:837-53.
47. [UKPDS] UKPDS Study Group. 1998b. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:854-65.
48. Wallace TM, Matthews DR. 2000. Poor glycemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM, 93: 369-74.
49. Witthaus E, Stewart J, Bradley C. 2001. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med, 18:619-25.
50. Wright A, Burden AC, Paisey R et al. 2002. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care, 25:330-6.
51. Yki-Jarvinen H, Dressler A, Ziemen M. 2000. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care, 23:1130-6.
52. Zinman B, Ross S, Campos RV, et al. 1999. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group. Diabetes Care, 22:603-8.